patients 
Bio Pharma Dive
MARCH 18, 2024
Balancing automated patient support with human touch is key in healthcare. Hybrid models offer a pragmatic path forward, prioritizing patient-centricity.
Rethinking Clinical Trials
JANUARY 8, 2024
In a new article from the NIH Pragmatic Trials Collaboratory, investigators from 6 of the program’s pragmatic clinical trials share case examples of the challenges they encountered in collecting patient-reported outcomes (PROs) in their trials and the strategies they used to address them.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
AuroBlog - Aurous Healthcare Clinical Trials blog
APRIL 2, 2024
In a concerted effort to bolster patient safety measures within the healthcare landscape, the Indian Pharmacopoeia Commission (IPC) is set to roll out its Skill Development Programmes on Pharmacovigilance.
Pharmaceutical Technology
FEBRUARY 28, 2024
As post-approval boundaries disproportionately affect rare disease patients, communities are rallying behind alternative options.
Advertisement
An increasing number of sponsors are seeking enhanced flexibility in their supply chains to address a variety of clinical supply challenges, including patient demand and reducing delays.
Rethinking Clinical Trials
APRIL 23, 2024
In an analysis of data from the TSOS study, younger patients and patients who were publicly insured or uninsured were among several subgroups of patients who were at significant risk of missing follow-up outcome assessments. The report was published this week in Injury. Learn more about the NIH Collaboratory Trials.
Pharmaceutical Technology
MARCH 14, 2024
Research puts the spotlight on potential financial conflicts of interest (COI) and limited disclosure practices in pharmaceutical patient-focusing relationships.
Advertisement
Deviations from the intended supply chain can delay timelines and affect these high value products, which can be detrimental to budgets, but more importantly can have dire effects on the patients whose lives depend on receiving these critical doses safely and on time.
Advertisement
The potential for reaching a larger pool of recruits is possible when sponsors can bring more trial activities to the patient. There’s been a rapid shift towards decentralization in clinical trials & it’s clear why.
Advertisement
Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. Clinical trial data management is increasingly challenging as studies grow in complexity. In this paper, we explore real-time data access and analysis for proactive study management.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
Learning Objectives: Dose-response curves and patient treatment: How do pharmacologic and toxicologic principles apply to the dosing of drugs in clinical development? Ben Locwin will discuss the potential effects of this draft, along with the pharmacological and toxicological considerations for optimizing doses of prescription drugs.
Expert insights. Personalized for you.
256 
Let's personalize your content